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Abstract 
Objective: Several studies have shown that repetitive transcranial magnetic stimulation (rTMS) over 
the dorsolateral prefrontal cortex (DLPFC) is effective in the treatment of depression in patients 
with Parkinson disease (PD). However, since research into the effect of this type of rTMS regime on 
motor function is limited, we studied the effect of rTMS over the DLPFC on the motor functions in PD 
patients. 
Methods: Thirteen patients were randomly assigned into 2 groups, one receiving real-rTMS (90% of 
resting motor threshold, 10 Hz, 450 pulses-day for 10 consecutive days) over the DLPFC contralateral to 
the more affected side, and the other group receiving sham-rTMS. Assessment included a clinical motor 
evaluation using part III of the Unified Parkinson’s Disease Rating Scale (UPDRS), and several motor 
tasks. The UPDRS was applied before and after 10 days of rTMS. Finger tapping, reach movement, grip 
movement and gait were measured in each session before and after the rTMS over the 10 day period. 
Results: Statistical analysis (ANOVA for repeated measures; group ∗ day ∗ side ∗ rTMS) only showed a 
significant effect for finger tapping, reach movement and gait for the factor day. No significant change 
was reported for the UPDRS in any group. 
Conclusions: Application of rTMS over the DLPFC as a 10 day course had no significant effect on motor 
functions and clinical motor status, and the improvement in performance of motor tasks can be attributed 
to the effects of practice. 
Significance: rTMS over the DLPFC did not lead to any motor improvement in PD patients. 
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1. Introduction 
Transcranial magnetic stimulation (TMS), a non-invasive means of stimulating neurons in the human 
cerebral cortex, is able to modify neuronal activity locally and at distant sites when delivered in series or 
trains of pulses. Previous studies have demonstrated the potential modulatory effects of repetitive 
transcranial magnetic stimulation (rTMS) on the excitability of cortical neurons (Maeda et al., 
2000 and Pascual-Leone et al., 1994a) and this effect depends on the parameters used in the stimulation 
such as intensity, frequency, site of stimulation, and can last beyond the duration of the rTMS (Pascual-
Leone et al., 1998, Chen et al., 1997 and Touge et al., 2001). The mechanisms of the modulation of 
cortical excitability beyond the duration of the rTMS train are still unclear but animal studies have 
suggested that modulation of neurotransmitters and gene induction may contribute to these long-lasting 
modulatory effects (Schlaepfer and Rupp, 2002). In humans different studies have shown changes in 
cerebral blood flow and glucose metabolism induced by transcranial magnetic stimulation (Fox et al., 
1997 and Siebner et al., 1998). These findings raise the possibility of therapeutic applications in 
neurological and psychiatric disorders. 
It is well known that the patients with Parkinson’s disease (PD) show several disturbances in their 
movement, particularity in the gait and in the repetitive and rhythmic upper limb movements (Morris et 
al., 1994, Morris et al., 1996 and Nakamura et al., 1978). Pascual-Leone et al., 1994b and Pascual-Leone 
et al., 1994c reported an improvement in motor performance during 5 Hz rTMS to the motor cortex, in 
patients with PD. However, a real efficacy of rTMS on motor cortex in PD is controversial since 
subsequent studies show contradictory results (using figure-of-eight coil: Ghabra et al., 1999, Siebner et 
al., 2000, Khedr et al., 2003, Lefaucheur et al., 2004 and Khedr et al., 2006. Using circular coil: Tergau et 
al., 1999, Shimamoto et al., 2001, Ikeguchi et al., 2003, Okabe et al., 2003 and Mally et al., 2004). These 
different results could be due to the different methodologies used in the TMS stimulation such as the 
shape of coil, the stimulus intensity, frequency and number of pulses (Fregni et al., 2005). 
The rTMS over the dorsolateral prefrontal cortex (DLPFC) has been established as a less invasive 
alternative to electroconvulsive therapy for the treatment of depression (Paus and Barret, 2004) and recent 
studies show that the rTMS over DLPFC has the same antidepressant efficacy as fluoxetine in patients 
with PD and concurrent depression (Fregni et al., 2004 and Boggio et al., 2005) and may have additional 
advantage of some motor improvement with fewer adverse effects (Fregni et al., 2004). It has been 
reported that successive low frequency (0.2 Hz) rTMS over frontal cortex (F3–F4 of the international 10–
20 system) at 70% of the maximal stimulator output improves several kinds of movements in patients 
with PD (Ikeguchi et al., 2003). On other hand, in normal subjects the application of several trains of 
10 Hz rTMS over the left dorsolateral prefrontal cortex (DLPFC) with a circular coil caused a reduction 
in [11C]raclopride binding in the left dorsal caudate nucleus and induced the release 
of endogenous dopamine in the ipsilateral caudate nucleus (Strafella et al., 2001). Recently, Lomarev et 
al. (2005) showed a therapeutic effect of high frequency rTMS effect on the motor function in patients 
with PD after 8 sessions of rTMS applied over the left and right motor cortex and DLPFC. However, 
since they used several cortical targets simultaneously, the effect of high frequency rTMS over the 
DLPFC on the motor performance in PD patients is still unknown. 
Based on the findings described above, we planned to evaluate the effect of high frequency (10 Hz) of 
rTMS over dorsolateral prefrontal cortex in the motor functions in a group of patients with PD, using the 
protocol of stimulation described previously by Strafella et al. (2001) for a period of 10 consecutive days. 
2. Materials and methods 
2.1. Subjects 
Thirteen patients with Parkinson’s disease were recruited for this study, 6 male and 7 female, aged 
61.7 (SD 5.22). All patients provided informed consent according to the declaration of Helsinki (1964). 
PD subjects were excluded if they had musculoskeletal, cardiovascular or visual disturbances that 
affected walking ability. A fundamental requirement for inclusion in the study was the ability to walk up 
and down a 30 m walkway five times without walking aids or assistance. For PD subjects the level of 
functional disability was also determined by mean of the motor section (part III) of the Unified 
Parkinson’s Disease Rating Scale (UPDRS) and Hoehn and Yahr scales. No patient showed dementia as 
assessed by mini-mental state examination (MMSE), freezing episodes nor therapy wash-out. The clinical 
details of the patients are shown in Table 1. Drug treatment was kept unchanged throughout the study. 
The Ethics Committee of Our Institution approved the experimental protocol. 
2.2. General procedure 
The patients were randomly allocated to either a real-rTMS condition (n = 8) and sham-rTMS 
condition (n = 5). In the first session (D0) we determined the resting motor threshold for rTMS for all 
patients. Over the next two sessions subjects were trained in the motor task to limit any effects of 
learning. In a separate session (T1) the results in the motor performance and the UPDRS were recorded. 
After this the patients performed the motor tasks before and after receiving the rTMS, for 10 days (Days 
1–10). One day after the last session with the rTMS the UPDRS was recorded again (T2). Considering the 
daily fluctuation of parkinsonian symptoms, we carried out sessions at the same time of the day. Patients 
were in “ON” state through out each session. 
2.3. Magnetic stimulation 
All experiments were performed using a focal stimulating coil, figure-of-8-shaped coil (external 
diameter of 9 cm) powered from a MagstimRapid device (The Magstim Company, Whiyland, UK). The 
coil was oriented so that it induced electric currents in the brain that flowed in a posterior-to-anterior 
direction over the hand area of motor cortex. The motor evoked potentials (MEPs) were recorded from 
the contralateral first dorsal interosseus (FDI) with Ag/Cl surface electrodes fixed on the skin with a belly 
tendon montage. Threshold was determined for the relaxed FDI. Threshold was defined as the lowest 
intensity required eliciting a clear response of more than 50 μV peak-to-peak amplitude at least 50% of 
successive trials (Rossini et al., 1994). The location for the rTMS stimulation in the prefrontal 
dorsolateral cortex (DLPFC) was determined (5 cm anterior in the same parasagittal plane as to the 
optimal scalp position for activation of FDI) (Pascual-Leone et al., 1996). The coil was centered over this 
position and the handle of the coil was placed posterior and lateral with respect to the midsagittal line. 
During the frontal real-rTMS condition, three rTMS blocks were delivered over the contralateral 
DLPFC to the more affected side. Each block consisted of 150 pulses distributed in 15 trains delivered at 
10 Hz with 1-s duration and 10 s interval between trains. Each block was separated by 10 min interval. 
Thus, a total of 450 stimuli were delivered over a period of 30 min. The intensity utilized was set at 90% 
of the resting motor threshold (RMT). 
During frontal sham-rTMs condition, the center of the magnetic coil was positioned 7 cm rostrally to 
the vertex over the midline with the coil angled at 45° with only the edge of the coil resting on the scalp 
(Siebner et al., 2000). The protocol utilized in the sham-rTMS condition was identical to the real-rTMS 
condition. 
Table 1. Clinical characteristics of patients with Parkinson disease 
Case 
No 
Age 
(years) Sex 
Disease 
duration 
(years) 
More 
affected 
side 
Handedness Predominant symptoms H&Y
a Medication per day (mg) 
         
1 66 M 5 R R Rigidity/Bradykinesia 2 
Levodopa/Carbidopa 
500/125, Entacapone 600, 
Pramipexole 2.1 
2 56 F 2 L R Tremor 2 Levodopa/Carbidopa 200/50, Cabergoline 4 
3 55 F 12 R R Rigidity/Bradykinesia 2 
Levodopa/Carbidopa 
500/125, Biperiden 4, 
Entacapone 200, Pergolide 
Mesylate 1 
4 72 M 11 R R Tremor 2 
Levodopa/Carbidopa 
600/150, Pergolide Mesylate 
3, Selegiline 10 
5 54 M 1 R R Tremor 1 Pramipexole 2.1 
6 56 M 11 L R Rigidity/Bradykinesia 2 
Levodopa/Benserazide 
400/100, Cabergoline 2, 
Selegiline 10 
7 70 F 8 R R–L Tremor 3 
Levodopa/Carbidopa 
400/100, 
Levodopa/Benserazide 
250/75, Pramipexole 1.05 
8 70 M 10 L R Tremor 2 
Levodopa/Benserazida 
450/112.5, Entacapona 800, 
Pramipexole 2.1, Selegiline 
10 
9 72 F 7 R R Tremor 3 
Levodopa/Carbidopa 300/75, 
Levodopa/Benserazide 
1000/250, Entacapone 800 
10 71 F 7 R R Rigidity/Bradykinesia 2 
Levodopa/Carbidopa 100/25, 
Levodopa/Benserazide 
600/150, Pramipexole 2.1 
11 66 M 3 R R Rigidity/Bradykinesia 2 Pramipexole 2.1, Selegiline 10 
12 74 F 21 R R Tremor 3 
Levodopa/Carbidopa 
400/100, 
Levodopa/Benserazide 
300/75, Pramipexole 1.05 
13 62 F 7 R R Rigidity/Bradykinesia 2 Levodopa/Carbidopa 500/50, Biperiden 4, Cabergoline 2 
         
 
a Hoehn and Yahr Rating Scale.  
2.4. Motor tasks 
2.4.1. Finger tapping 
All participants performed repetitive flexion-extension movements with their index finger in two 
different conditions: 
 
(a) at preferred speed. Subjects were instructed to tap at their preferred diadochokinesis rate for a 
period of 30 s. 
(b) at maximum speed. Subjects were instructed to tap “as quickly as possible” for a period of 10 s. 
 
Tapping was performed separately with index finger on both sides separately. A flexible metal loop 
was fitted snugly to the index finger just proximal to the terminal interphalangeal joint. Each time the 
metal loop on the index finger struck the contact plate it completed an electrical circuit and generated a 
brief voltage pulse. Subjects were seated with their forearms resting on a support (elbow angle about 90°). 
To prevent wrist flexion/extension, the wrist was immobilised by a cast. This procedure assured that the 
sequencing task could be accomplished only by a tapping motion of the index finger. The dependent 
variables that were measured for each condition of finger tapping included the tapping frequency in Hz 
and the coefficient of variation (CV) of interval of two consecutive taps (in ms) as a indicator of temporal 
variability of tapping, where CV = (standard deviation/mean) × 100. 
2.4.2. Grip 
Maximum isometric grip strength was measured using a standard hand dynamometer with the grip 
span fixed at 6 cm. To perform these trials, subjects gripped the dynamometer between the index finger 
and thumb, and then they increased the grip force as quickly as possible for 5 s. The grip strength was 
measured for each hand separately. The dependent variables that were measured included the maximum 
force isometric and the maximum slope. 
2.4.3. Reaching 
All participants performed reaching movements with one arm stretched to touch a point situated in 
front of them in two different conditions: 
 
(a) At preferred speed. Subjects were instructed to reach and touch a point at their preferred 
diadochokinesis. Ten consecutives trials were collected. 
(b) At maximum speed. Subjects were instructed to reach and touch “as fast as possible” in response 
to an auditory “go” tone presented randomly every 5–15 s. Five consecutives trials were collected. 
 
Reaching movements were performed with each arm separately. An accelerometer was placed in the 
wrist. The dependent variables that were measured included the coefficient of variation of velocity in the 
movement at preferred diadochokinesis and the maximum velocity in the movement at maximum speed. 
2.4.4. Gait 
All participants walked at preferred and maximum speed, back and forth over a 7 m flat walkway to 
complete a total distance of 28 m (with three turns). Two pairs of photoelectric cells, one at the beginning 
and one at the end of the walkway, were used to measure the time required to complete the task. 
2.5. Analysis 
To test whether the real and sham rTMS groups had similar motor performance we used Student’s t-
test for independent samples. Two separate analyses were performed in order to establish the effect of the 
rTMS on the clinical status and motor performance. First, two-tailed paired Student’s t-test were 
performed to investigate changes in the clinical status before (T1) and after (T2) the rTMS sessions. We 
focused our statistical analysis on the analysis of variance (ANOVA) of measures repeated with three 
within-subjects and one between-subject factors. The within subjects factors were side (two levels, side 
more affected and side less affected), rTMS (two levels, before and after application of rTMS) and day 
(10 levels). The inter subject factor was group (two levels, real-rTMS and sham-rTMS). For the analysis 
of the gait task the factor side was not included.  
3. Results 
Table 2 shows the mean and standard deviation at time T1 before the rTMS sessions, for each motor 
task in both groups. The CV of the reach task at the preferred speed with the less affected side was the 
only parameter significantly different between the groups (t = 4.218, p < 0.05) in session T1. The motor 
UPDRS scores did not show significant differences between groups at T1. This shows that the groups 
were homogeneous in motor performance and clinical motor status. The UPDRS scores after DLPFC 
rTMS are summarized in the Fig. 1. There was no significant effect for either group. 
Table 2. Values of the motor tasks in both groups before the sessions with rTMS 
Motor task Variable Side Real – rTMS (n = 8) Sham – rTMS (n = 5) 
 
Finger tapping 
Preferred speed CV MA 11.93 ± 15.29 14.21 ± 6.89 
 LA 9.15 ± 12.02 18.21 ± 6.83 
Frequency (Hz) MA 2.38 ± 0.65 2.40 ± 1.11 
 LA 2.27 ± 0.41 2.35 ± 1.16 
Maximum speed  MA 17.75 ± 15.74 13.17 ± 11.54 
 LA 14.72 ± 13.40 14.48 ± 6.65 
Frequency (Hz) MA 3.93 ± 1.31 3.54 ± 1.48 
 LA 3.94 ± 0.87 3.22 ± 1.44 
Reach 
Preferred speed Velocity (m/s) MA 0.43 ± 0.14 0.48 ± 0.15 
 LA 0.43 ± 0.11 0.44 ± 0.07 
CV MA 7.22 ± 4.42 12.73 ± 5.74 
 LA* 6.59 ± 2.03 12.88 ± 2.90 
Maximum speed Velocity (m/s) MA 0.70 ± 0.27 0.59 ± 0.20 
 LA 0.65 ± 0.27 0.58 ± 0.13 
CV MA 12.33 ± 8.99 13.53 ± 7.56 
 LA 10.80 ± 7.48 18.36 ± 9.77 
Grip 
 Maximum force (N) MA 6.97 ± 3.07 5.93 ± 2.57 
  LA 7.31 ± 2.98 5.84 ± 1.20 
 Maximum slope (N/ms) MA 15.34 ± 8.37 22.45 ± 18.53 
  LA 15.87 ± 8.76 22.39 ± 13.85 
Gait 
Preferred speed Time (s)  31.36 ± 4.78 36.03 ± 8.81 
Maximum speed Time (s)  11.36 ± 2.16 13.86 ± 4.46 
     
 
MA, more affected side. LA, less affected side. CV, coefficient of variation. *p < 0.05. Significant T1 values using t-test for 
independent samples. 
 
 
Fig. 1. Mean (±SEM) values of the scores of the motor part of the Unified Parkinson’s Disease Rating Scale in the real-rTMS and 
sham-rTMS groups before (white columns) and after (black columns) DLPFC 10-Hz repetitive transcranial magnetic stimulation. 
 
 
 
 
 
 
The ANOVA (side × rTMS × day × group) showed the following results: 
 
(i) The frequency of finger tapping at preferred speed and the CV at maximum speed showed a 
significant effect for the factor day (F = 13.027, p = 0.005 and F = 19.79, p = 0.001) without 
significant interaction between the other factors ( Fig. 2). In the other parameters of the finger 
tapping there was no significant effect in the factors nor a significant interaction. 
 
 
 
Fig. 2. Sequential assessment in the finger tapping test for the more affected side before and after DLPFC 10-Hz 
repetitive transcranial magnetic stimulation. Upper graphs show the frequency in the finger tapping test at preferred speed. Lower 
graphs show the coefficient of variation in the finger tapping at maximum speed. Left graphs correspond to real-rTMS group and 
right graphs to sham-rTMS group. The ANOVA shows a significant difference in the day factor (p < 0.05). Similar results were 
observed for the less affected side (not illustrated). 
(ii) There was no significant difference on the maximum isometric force and the maximum slope in 
the grip task. 
(iii) For the reach task at preferred speed only the factor day showed a significant effect for the 
velocity (F = 7.684, p = 0.01) and CV (F = 12.87, p = 0.002) ( Fig. 3). Here was no significant 
effect for the reach task at maximum. 
 
 
Fig. 3. Sequential assessment in the reaching task at preferred speed test for the more affected side before and after DLPFC 10-Hz 
repetitive transcranial magnetic stimulation. Upper graphs show the velocity and lower graphs the coefficient of variation. Left 
graphs corespondent to real-rTMS group and right graphs to sham-rTMS group. The ANOVA shows a significant difference in the 
day factor (p < 0.05). Similar results were observed for the less affected side (not illustrated). 
  
(iv) The gait at preferred and maximum velocity tasks showed a significant effect in the factor day 
(F = 8.47, p = 0.007 and F = 3.81, p = 0.038, respectively, Fig. 4). 
 
 
Fig. 4. Sequential assessment in gait at preferred speed (upper graphs) and maximum speed (lower graphs) before and after DLPFC 
10-Hz repetitive transcranial magnetic stimulation. Left graphs correspond to real-rTMS group and right graphs to sham-rTMS 
group. The ANOVA shows a significant difference in the day factor (p < 0.05). 
4. Discussion 
The present study shows that high frequency rTMS of the DLPFC over 10 days does not have a 
significant effect on the performance of motor tasks in PD patients and on the clinical motor status. The 
changes shown in this study can not be attributed to the effect of rTMS but rather to the possible effect of 
practice. 
Ikeguchi et al. (2003) using 0.2 Hz in 6 successive sessions for 2 weeks showed a significant 
improvement in pronation–supination movements, buttoning up task and a increase in speed of walking 
over 10 m. The authors attribute this improvement to the effect of TMS although Okabe et al. (2003) 
showed that this can be clearly attributed to a placebo effect. In our study, it is not possible to establish 
this cause-effect since the r-TMS had no significant effect over these tasks. It is possible that the changes 
in the motor performance observed in our study were due to practice effects (see below). Although other 
studies have reported changes in gait velocity and in finger tapping after rTMS (Khedr et al., 
2003, Jäncke et al., 2004 and Lomarev et al., 2005), the protocol of stimulation used is different in the 
frequency, intensity, number of delivered stimuli, and the stimulated area. We have to note that the 
individual motor threshold was calculated before beginning the rTMS sessions. It is possible that the 
intensity used for rTMS was not exactly 90% of RMT for each day, since Wassermann (2002) reported 
important variability in the RMT in normal subjects across different sessions. However, Lomarev et al. 
(2005) have not reported significant changes in the RMT in a group of 18 PD patients in a period of 4 
weeks. Furthermore, intensity in the range of 80–115% of the RMT seems effective in affecting 
the prefrontal cortex (George et al., 1997 and Fregni et al., 2004). Thus, the possible variability of the 
individual RMT is not higher than the range cited. The number of delivered stimuli in our study was 
lower than that considered efficient in the treatment of depression in patients with PD (Fregni et al., 
2004 and Boggio et al., 2005). However, Strafella et al. (2001) reported a release 
of endogenous dopamine in the caudate nucleus and Koch et al. (2003) showed an underestimation of 
time perception after application of 600 pulses at 1 Hz at 90% of RMT over the DLPFC. Thus, the 
number of delivered pulses in the present study would be sufficient to have an effect on the functionality 
of the DLPFC. Lomarev et al. (2005) found an improvement in the gait and in performance of complex 
hand movements but they stimulated four different cortical areas, therefore it is not possible to dissociate 
the role of the DLPC in this improvement. 
We have included several aspects in the present study to test for a possible effect of rTMS: the 
presence of the sham-rTMS group, daily control session for a possible immediate effect of the rTMS and 
the performance of the upper limb motor tasks with both sides. To assess the actual effects of rTMS, 
placebo stimulation is a very important factor. A recent report showed that expectation of improvement 
releases dopamine in the caudate nucleus in PD (de la Fuente-Fernandez and Stoessl, 2002). Moreover, 
some authors suspect that the simple “off-head” stimulation could not be an effective “placebo”, because 
patients may learn rapidly to distinguish between stimuli with and without a current flow (Boylan et al., 
2001). Although we used the 45° for the Sham-rTMS in order to avoid any stimulation effect, recent 
studies show that a 90° position would be more adequate since the 45° orientation of the coil can produce 
substantial stimulation of the cortex (Loo et al., 2000 and Lisanby et al., 2001). Thus, the absence of 
significant difference between the “active” and the “sham” procedures might be cause by a yet active 
placebo condition. Regarding motor performance, both groups were similar since only one parameter in 
one task was significantly different between them and this difference was constrained to the less affected 
side. The daily control of a possible immediate effect of the TMS was considered since other studies 
show a motor improvement and increase in corticospinal excitability after a single session of rTMS over 
the motor cortex of parkinsonian patients (Siebner et al., 2000 and Lefaucheur et al., 2004). All the 
subjects performed the motor tasks before and after the application of the TMS over 10 days, allowing 
rTMS effects to reach clinical level. However, the improvement in the motor tasks observed is most likely 
due to practice. In other studies patients with PD were able to improve the velocity of their movements 
after continued practice (Agostino et al., 1996). It is possible that the inclusion in this study of another 
real-rTMS group in which patients only performed the motor tasks on the first and the last day would help 
to determine the effect of motor practice, which could mask the real effect of the rTMS (Ghabra et al., 
1999). However, although we carried out sessions at the same time of the day, considering the daily 
fluctuation of parkinsonian symptoms, the fluctuations in the motor performance over 10 days were 
evident. The reason we evaluated the effect of the rTMS in the hand contra and ipsilateral to the 
stimulated hemisphere was due to evidence that shows an influence of the rTMS over the motor cortex in 
the execution of movements in the ipsilateral hand (Kobayashi et al., 2004). This effect can be explained 
through the interhemispheric interaction between motor and premotor areas (Ferbert et al., 1992, Netz et 
al., 1995 and Hanajima et al., 2001). It would be of interest to know if this interhemispheric effect was 
present in the DLPFC. However, our results do not show a significant effect in the side factor nor in the 
rTMS factor and this issue can not be resolved. 
In our study, the clinical assessment by UPDRS did not show any significant change after the DLPFC 
rTMS in both groups. However, regardless of the absence of motor and clinical improvement induced by 
rTMS, other different parameters could have been affected. Studies have reported that focal rTMS to the 
prefrontal cortex induced dopaminergic release in the caudate nucleus of healthy humans (Strafella et al., 
2001) and changes in cerebral blood flow (Ikeguchi et al., 2003 and Rollnik et al., 2002). Although we 
believe that in our group the changes in motor performance were due to practice effect it is possible that 
the dopaminergic release reported by Strafella et al. (2001) could have occurred. It has been shown that 
there is no significant relation between improved clinical test and cerebral blood flow in the frontal areas 
after the application of rTMS (Ikeguchi et al., 2003). Moreover, changes in cortical excitability after 
rTMS do not have an affect on clinical parkinsonian symptoms or motor performance (Mir et al., 2005). 
Perhaps the use of other motor tasks specifically related to the DLPFC physiology (motor planning and 
response selection) would be more sensitive to changes of rTMS to this area (Goldman-Rakic, 1998). We 
evaluated several different motor tasks to explore if the possible effect of the rTMS was constrained to a 
specific movement. In fact all the tasks used in this studied are commonly used to measure the impaired 
motor performance in patients with Parkinson’s disease. Higher temporal variability in the finger-tapping 
test in patients with PD has been previously demonstrated in various studies (Nakamura et al., 
1978 and Ivry and Keele, 1989) as well as slower frequency of finger tapping at maximum velocity in 
comparison with elderly subjects (Shimoyama et al., 1990). Parkinson’s disease affects the reaching 
movement kinematics (Tresilian et al., 1997) and reduced strength and ability to generate rapid 
contractions in isometric contractions have also been reported (Yanagawa et al., 1990 and Corcos et al., 
1996). Overall it is well known that patients with PD show significantly slower velocity and difficulty in 
turning (Morris et al., 1994, Morris et al., 1996 and Mesure et al., 1999). 
In summary, although in the last decade the studies of the therapeutic role of r-TMS in Parkinson 
disease have grown considerably, there are few studies of rTMS over the prefrontal dorsolateral cortex in 
patients with Parkinson’s disease. Our results suggest that during 10 days of high frequency repetitive 
TMS over the DLPFC the patients only improved the performance of motor tasks due to practice and not 
due to the effect of rTMS, without affecting the clinical motor status. 
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